Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Wainberg

Showing results (41-50 of 341) with videos related to

Pageof 35
Sort By:
Current Opinion in Virology|October 3, 2012
Staying ahead of viruses: a never ending taskDaniel Lamarre, Mark A Wainberg
AIDS Reviews|May 10, 2002
The role of Tat in HIV-1 replication: an activator and/or a suppressor?Chen Liang, Mark A Wainberg
AIDS (London, England)|October 27, 2016
We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistanceBluma Brenner, Mark A Wainberg
Ebiomedicine|July 19, 2016
Will LEDGIN molecules be able to play a role in a cure for HIV infection?Thibault Mesplède, Mark A Wainberg
Virus Research|July 17, 2016
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistanceBluma G Brenner, Mark A Wainberg
The Journal of Infectious Diseases|September 9, 2006
Chemoprophylaxis of HIV infection: moving forward with cautionRobert M Grant, Mark A Wainberg
Retrovirology|December 23, 2006
Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239James B Whitney, Mark A Wainberg
Retrovirology|February 5, 2013
Cellular and molecular mechanisms involved in the establishment of HIV-1 latencyDaniel A Donahue, Mark A Wainberg
Molecular Biology International|July 14, 2012
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral DrugsMark A Wainberg, Bluma G Brenner
Frontiers in Pharmacology|May 15, 2015
Will drug resistance against dolutegravir in initial therapy ever occur?Mark A Wainberg, Ying-Shan Han
Pageof 35

Showing results (41-50 of 341) with videos related to

Sort By:
Pageof 35
Current Opinion in Virology|October 3, 2012
Staying ahead of viruses: a never ending taskDaniel Lamarre, Mark A Wainberg
AIDS Reviews|May 10, 2002
The role of Tat in HIV-1 replication: an activator and/or a suppressor?Chen Liang, Mark A Wainberg
AIDS (London, England)|October 27, 2016
We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistanceBluma Brenner, Mark A Wainberg
Ebiomedicine|July 19, 2016
Will LEDGIN molecules be able to play a role in a cure for HIV infection?Thibault Mesplède, Mark A Wainberg
Virus Research|July 17, 2016
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistanceBluma G Brenner, Mark A Wainberg
The Journal of Infectious Diseases|September 9, 2006
Chemoprophylaxis of HIV infection: moving forward with cautionRobert M Grant, Mark A Wainberg
Retrovirology|December 23, 2006
Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239James B Whitney, Mark A Wainberg
Retrovirology|February 5, 2013
Cellular and molecular mechanisms involved in the establishment of HIV-1 latencyDaniel A Donahue, Mark A Wainberg
Molecular Biology International|July 14, 2012
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral DrugsMark A Wainberg, Bluma G Brenner
Frontiers in Pharmacology|May 15, 2015
Will drug resistance against dolutegravir in initial therapy ever occur?Mark A Wainberg, Ying-Shan Han
Pageof 35